@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB00897 rdf:type ns2:Drug ; ns2:description "Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances."@en ; ns2:dosage , ; ns2:generalReferences "# Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2883820 # Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2570451 # Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15037809 # Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17287588 # Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek] Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2773144"@en ; ns2:group "approved"@en ; ns2:halfLife "1.5-5.5 hours"@en ; ns2:indication "For the short-term treatment of insomnia."@en ; ns2:manufacturer , , , . @prefix owl: . @prefix ns4: . ns1:DB00897 owl:sameAs ns4:DB00897 . @prefix ns5: . ns1:DB00897 owl:sameAs ns5:DB00897 . @prefix dcterms: . ns1:DB00897 dcterms:title "Triazolam"@en . @prefix adms: . ns1:DB00897 adms:identifier . @prefix ns8: . ns1:DB00897 adms:identifier ns8:DB00897 , , . @prefix ns9: . ns1:DB00897 adms:identifier ns9:PA451753 . @prefix ns10: . ns1:DB00897 adms:identifier ns10:D00387 , , . @prefix ns11: . ns1:DB00897 adms:identifier ns11:Triazolam ; ns2:mechanismOfAction "Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA_A) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell."@en ; ns2:packager , , , , , , , , , , , , , , , , , , , , , , , , , ; ns2:routeOfElimination "Triazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion."@en ; ns2:synonym "Triazolam"@en , "Triazolamum"@en , "Halcion"@en ; ns2:toxicity "Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression."@en . @prefix ns12: . ns1:DB00897 ns12:hasAHFSCode . @prefix ns13: . @prefix ns14: . ns1:DB00897 ns13:hasConcept ns14:M0021910 . @prefix foaf: . ns1:DB00897 foaf:page , , ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , , ; ns2:logS , . @prefix ns16: . ns1:DB00897 ns12:hasATCCode ns16:N05CD05 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "Bioavailability is 44% (oral) and 53% (sublingual)."@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "28911-01-5"@en ; ns2:category " "@en ; ns2:containedIn , , , , , , , , , , ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Melting-Point ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-acidic- ; ns2:pKa--strongest-basic- .